OverviewSuggest Edit

Allakos, a biopharmaceutical company, focuses on developing therapeutic antibodies targeting allergic, inflammatory, and proliferative diseases. The Company is developing AK002 for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis, urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis.
TypePublic
Founded2012
HQRedwood City, CA, US
Websiteallakos.com

Latest Updates

Employees (est.) (Mar 2020)96(+7%)
Job Openings7
Share Price (Jul 2021)$81.5
Cybersecurity ratingAMore

Key People/Management at Allakos

Dan Janney

Dan Janney

Chairman
Robert Alexander

Robert Alexander

Chief Executive Officer, Director
Robert Andreatta

Robert Andreatta

Director
Mark Asbury

Mark Asbury

Chief Legal Officer, General Counsel
Paul Walker

Paul Walker

Director
Craig Paterson

Craig Paterson

Chief Medical Officer
Show more

Allakos Office Locations

Allakos has an office in Redwood City
Redwood City, CA, US (HQ)
975 Island Dr #201
Show all (1)

Allakos Financials and Metrics

Allakos Revenue

USD

Net income (Q1, 2021)

(55.6m)

EBIT (Q1, 2021)

(55.6m)

Market capitalization (29-Jul-2021)

4.4b

Closing stock price (29-Jul-2021)

81.5

Cash (31-Mar-2021)

170.0m

EV

4.2b
Allakos's current market capitalization is $4.4 b.
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

General and administrative expense

2.4m3.7m12.4m29.6m51.5m

R&D expense

14.7m18.5m33.3m61.9m105.5m

Operating expense total

17.1m22.3m45.7m91.4m157.1m

EBIT

(17.1m)(22.3m)(45.7m)(91.4m)(157.1m)
Quarterly
USDQ2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q1, 2021

General and administrative expense

2.4m3.3m5.8m5.9m7.5m11.6m12.1m16.7m

R&D expense

7.1m8.7m15.1m14.1m16.1m18.3m28.3m38.9m

Operating expense total

9.5m12.0m20.9m20.1m23.6m29.9m40.4m55.6m

EBIT

(9.5m)(12.0m)(20.9m)(20.1m)(23.6m)(29.9m)(40.4m)(55.6m)
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

13.4m85.2m33.7m38.4m207.2m

Prepaid Expenses

150.0k1.0m2.7m4.0m10.3m

Current Assets

13.6m86.2m181.6m499.9m669.3m

PP&E

333.0k445.0k8.8m8.4m8.3m
Quarterly
USDQ2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q1, 2021

Cash

19.3m51.6m31.5m36.5m308.8m135.9m153.9m170.0m

Prepaid Expenses

3.0m3.6m1.5m1.3m3.1m4.0m3.3m13.0m

Current Assets

67.1m197.2m168.7m154.3m520.1m483.8m458.3m628.9m

PP&E

3.4m7.6m9.0m8.7m8.4m8.1m7.7m13.6m
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(17.1m)(23.6m)(43.5m)(85.4m)(153.5m)

Depreciation and Amortization

148.0k241.0k242.0k1.5m

Accounts Payable

(1.1m)510.0k76.0k3.6m7.6m

Cash From Operating Activities

(17.6m)(22.6m)(38.4m)(63.0m)(113.9m)
Quarterly
USDQ2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q1, 2021

Net Income

(17.9m)(29.0m)(20.0m)(39.0m)(60.8m)(27.8m)(67.1m)(55.6m)

Depreciation and Amortization

119.0k183.0k357.0k732.0k393.0k372.0k

Accounts Payable

(647.0k)915.0k1.3m874.0k1.7m3.1m3.7m(6.8m)

Cash From Operating Activities

(17.4m)(25.8m)(13.3m)(27.7m)(43.9m)(18.6m)(43.7m)(46.3m)
USDFY, 2016

Financial Leverage

-0.4 x
Show all financial metrics

Allakos Cybersecurity Score

Cybersecurity ratingPremium dataset

A

91/100

SecurityScorecard logo

Allakos Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Allakos Online and Social Media Presence

Embed Graph

Allakos News and Updates

Allakos Completes Patient Enrollment in Phase 3 Eosinophilic Gastritis and/or Eosinophilic Duodenitis and Phase 2/3 Eosinophilic Esophagitis Clinical Trials of Lirentelimab (AK002)

-- Results from both clinical trials expected in the fourth quarter of 2021 -- -- CMO Dr. Henrik Rasmussen to retire; Dr. Craig Paterson, SVP of Clinical Development and Medical Affairs, promoted to CMO --

New Allakos Data Presented at DDW 2021 Suggest that Eosinophilic Gastritis and/or Eosinophilic Duodenitis (EG/EoD) is Highly Underdiagnosed and may be a Common Cause of Moderate-to-Severe Gastrointestinal Symptoms

45% (181/405) of patients with chronic functional gastrointestinal symptoms who underwent upper endoscopy with biopsy met the diagnostic criteria for eosinophilic gastritis and/or eosinophilic duodenitis (EG/EoD) 45% (181/405) of patients with chronic functional gastrointestinal symptoms who underwe…

Allakos Announces Multiple Presentations Related to Eosinophil and Mast Cell-Driven Diseases at the 2021 DDW Annual Meeting

REDWOOD CITY, Calif., March 30, 2021 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company” or “Allakos”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today announced the acceptance of two oral and five poster pres…

Allakos Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

REDWOOD CITY, Calif., March 01, 2021 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today reported financial results for the fourth quarter and full year ended …

Allakos Announces Results from a Phase 1 Study of Subcutaneously Administered Lirentelimab (AK002)

-- Subcutaneous formulation of lirentelimab was safe and well tolerated and demonstrated sustained eosinophil suppression supporting once monthly dosing -- -- Management to host conference call and webcast today at 8:00 am ET --

Allakos Reports Second Quarter 2020 Financial Results and Provides Business Update

REDWOOD CITY, Calif., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell-related diseases, today reported financial results for the second quarter ended June 30, 2020 and provided an …
Show more

Allakos Blogs

Allakos Reports First Quarter 2021 Financial Results and Provides Business Update

Allakos Reports First Quarter 2021 Financial Results and Provides Business Update Content Import Mon, 05/10/2021 - 16:02 Allakos Reports First Quarter 2021 Financial Results and Provides Business Update May 10, 2021 at 4:01 PM EDT This release is a backfill fr…

Allakos Appoints Baird Radford as Chief Financial Officer

Allakos Appoints Baird Radford as Chief Financial Officer Content Import Mon, 04/19/2021 - 16:02 Allakos Appoints Baird Radford as Chief Financial Officer April 19, 2021 at 4:01 PM EDT This release is a backfill from a News Wire General …

Allakos Appoints Natalie Holles to its Board of Directors

REDWOOD CITY, Calif. , Dec. 22, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today announced the appointment of Natalie Holles , president and chief executive officer of

Allakos Reports Third Quarter 2020 Financial Results and Provides Business Update

Allakos Reports Third Quarter 2020 Financial Results and Provides Business Update Content Import Mon, 11/09/2020 - 08:04 Allakos Reports Third Quarter 2020 Financial Results and Provides Business Update November 9, 2020 at 8:01 AM EST This release is a backfil…

Allakos Announces Presentation from its Eosinophilic Gastrointestinal Diseases Program at the American College of Gastroenterology (ACG) 2020 Annual Scientific Meeting

REDWOOD CITY, Calif. , Nov. 02, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, announced a poster presentation at last week’s American College of Gastroenterology 2020

Allakos Announces Pricing of Public Offering of Common Stock

Allakos Announces Pricing of Public Offering of Common Stock Content Import Wed, 10/28/2020 - 20:20 Allakos Announces Pricing of Public Offering of Common Stock October 28, 2020 at 8:20 PM EDT This release is a backfill from a News Wire General …
Show more

Allakos Frequently Asked Questions

  • When was Allakos founded?

    Allakos was founded in 2012.

  • Who are Allakos key executives?

    Allakos's key executives are Dan Janney, Robert Alexander and Robert Andreatta.

  • How many employees does Allakos have?

    Allakos has 96 employees.

  • Who are Allakos competitors?

    Competitors of Allakos include ALX Oncology, Vyriad and Sosei Heptares.

  • Where is Allakos headquarters?

    Allakos headquarters is located at 975 Island Dr #201, Redwood City.

  • Where are Allakos offices?

    Allakos has an office in Redwood City.

  • How many offices does Allakos have?

    Allakos has 1 office.